Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

FDA Support for Natural Killer Cell Therapy for Gastrointestinal Cancers

FDA Support for Natural Killer Cell Therapy for Gastrointestinal Cancers

The FDA (US Food and Drug Administration), a global leader in developing new drugs and determining whether they are effective and safe, announced support for treating advanced HER2-positive stomach and gastroesophageal (stomach-esophagus) junction cancers with a natural killer (natural killer= NK) cell therapy called CYNK-101.

How Does the Living Drug CYNK-101 Work?

Developed by the biotechnology company Celularity, which is working on many cellular therapies, CYNK-101 consists of genetically engineered NK cells.

To create this living cellular immunotherapy treatment, allogeneic (from another individual) human placental hematopoietic stem cells were genetically engineered to express a high-affinity, shedding-resistant variant of CD16 (FCGRIIIA) (see the figure below).

This modified NK-cell treatment is used in HER2-positive stomach cancers together with pembrolizumab (Keytruda, Merck), a monoclonal-antibody immunotherapy.

The FDA's fast-track support for this treatment helps accelerate the development, review and potential approval of therapies for serious or life-threatening diseases.

The agency had previously granted fast-track support for treating relapsed (recurrent) or refractory acute myeloid leukemia and the aggressive brain tumors called glioblastomas to Celularity's two other NK-cell therapy products.

Celularity's founder and CEO, Robert J. Hariri: “We are very excited to receive FDA fast-track support for our investigational genetically engineered NK-cell therapy. Together, the CYNK-101 cells we obtained through advances in genetic engineering and other approved antibody immunotherapies may provide a synergistic anticancer effect capable of overcoming treatment resistance,” he said.

Celularity is enrolling patients in an open-label, nonrandomized phase 1 / 2A clinical study of CYNK-101. The study will evaluate the safety and initial efficacy of a combination of standard chemotherapy, trastuzumab (Herceptin) and pembrolizumab as first-line treatment for patients with locally advanced unresectable or metastatic HER2-positive stomach and gastroesophageal junction adenocarcinoma.

*

Further Reading: How Is CYNK-101 Developed?

Celularity describes CYNK-101 (genetically modified NK cells) as follows:

Natural Killer (NK) cells are part of the innate immune system and generate cytotoxic (cell-killing) and cytokine-triggering responses against stressed cells such as virally infected cells and tumor cells. NK-cell function is distinguished by the innate mechanisms through which they recognize cancerous or virus-infected cells, become activated and then destroy those cells. We are developing cell lines dedicated to enhancing NK cells' anticancer functions through various genetic modification approaches.

CYNK-101 is an allogeneic, off-the-shelf NK-cell product derived from human placental hematopoietic stem cells and genetically modified to express a high-affinity, shedding-resistant variant of CD16 (FCGRIIIA).

We are developing CYNK-101 as a combination therapy for different types of cancer. We extract the NK cells for CYNK-101 from placentas after childbirth.

Preclinical studies show that CYNK-101 plus a therapeutic antibody has cell-killing activity against lymphoma cells in vitro. We expect CYNK-101 to be effective in cancer patients by increasing antibody-dependent cytotoxicity and enhancing the efficacy of already approved antibody immunotherapies.

CYNK-101 enhances ADCC against tumor targets in combination with monoclonal antibodies

how Celularity's genetically modified CYNK 101 NK cells work in HER2-positive stomach cancer

One of the key mechanisms of NK-cell effector function is Antibody-Dependent Cellular Cytotoxicity, a response driven by CD16 receptors. However, the affinity and durability of the response through natural CD16 receptors are regulated by polymorphism and activation-induced receptor shedding. We developed the CYNK-101 cell line for use with tumor-targeting monoclonal antibodies to enhance and sustain antibody-dependent cellular cytotoxicity responses.

Sources

FDA grants fast track designation to natural killer cell therapy for GI cancers. Healio News: https://www.healio.com/news/hematology-oncology/20220119/fda-grants-fast-track-designation-to-natural-killer-cell-therapy-for-gi-cancers (19.01.2022)

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

FDA Support for Natural Killer Cell Therapy for Gastrointestinal Cancers

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy